Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
about
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseInhaled corticosteroids with combination inhaled long-acting beta 2 -agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary diseaseBronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPDComparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysisComparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysisPositioning new pharmacotherapies for COPDA re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary diseaseAirway hydration and COPDPotential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseasesFormoterol is more effective than salmeterol in suppressing neutrophil reactivityUsing Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease.Model-Based Network Meta-Analysis: A Framework for Evidence Synthesis of Clinical Trial DataTreatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population.Real-life GOLD 2011 implementation: the management of COPD lacks correct classification and adequate treatment.Use and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary disease.Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study.Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialV0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical resultsAccounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.Agonist binding to β-adrenergic receptors on human airway epithelial cells inhibits migration and wound repair.Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD.Enhanced recovery pathway for thoracic surgery in the UK.COPD exacerbations by disease severity in EnglandCurrent concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study.Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long-Acting β2 -Agonists and Inhaled Corticosteroids: The OUTPUL StudyThe impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approach.Sing Your Lungs Out-a community singing group for chronic obstructive pulmonary disease: a 1-year pilot study."Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORDDrugs for chronic obstructive pulmonary diseaseInhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review.Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.
P2860
Q24186411-E62CEFDB-370F-4A51-A2D2-A20EA3F849B1Q24186966-46277F8B-47AC-431F-9156-2F1388E6F1EEQ24188108-D412EDD3-8F5C-473C-B4E5-DC6557E60B1EQ26778794-71B3BCF9-384C-4F4A-8DB3-0AAD70533C52Q26782484-E3C8EDB7-63E5-45FF-97B7-DA5C35B477CBQ26798659-4AD66184-D4B0-4BB5-9DA9-0509AFAFF56CQ26801661-149BF876-5F3F-42BF-BDDA-00EB8959ED4FQ28082617-14223799-F2F4-4485-B88B-61BEB26B89CCQ28083987-B5D60AEB-42B6-4DEE-A208-1122A883170AQ28596768-0D856EE8-4703-41C9-A564-10BC230FDA86Q31097021-36CE4508-A78C-4F09-928A-ACF28E23878BQ31118906-CBF8C14F-4F9D-412D-ADEE-245BE622E019Q33649874-893DC75D-EA4A-4D29-8752-CCC195546D0DQ33795984-04666543-0E8D-40AE-AFB9-6634873457ECQ34472717-A98F355E-1520-4B45-9A93-BCCB618913F2Q34984779-7F021CC2-767C-4A1F-9620-21A88FE76E7BQ35208787-14B1417C-D268-4C25-A9F6-5DCBDE080AF5Q35538141-E6773018-5AF0-4C5B-AEE9-758044857A73Q35595077-68C775DC-83EF-462C-8AF0-6B540B077A95Q35710238-E59F632D-E416-4D2B-823B-7A4C310F240FQ35752782-EF86522E-3C29-401E-AEE5-FCE381F88C73Q35778149-ADF8A208-1C74-41E9-A9C5-B26879B4A59CQ36188224-A31FDBE9-A6DF-4A99-BABA-3ADA236C9276Q36307097-24311581-2380-4882-A693-47FFD3350E8EQ36381803-F517BDE6-0F74-40D9-92B9-0B6676DF49EBQ36431478-D75C1D6C-5DDB-4C79-A1E6-38579AC661F2Q36587342-E206EF38-B10F-4FA9-B307-B781EB0F4523Q36776335-CEEABE18-50CC-4B92-A5E5-85A2D12DE2BFQ36907742-484DABAF-9045-4348-86FD-F63617BE81D9Q37343961-15ED2132-CBE1-4C20-984C-952034A222A8Q37418094-09F2EF08-6ED1-4A1A-B4F1-0E60AD2CED1FQ37456602-45E3B92D-632B-44CA-9F10-D22ED96C8BC3Q37627353-86F4E9A2-27DD-46D4-A04E-0347D23F6918Q37628665-BCCB4787-0275-48A6-B84C-5A6B2B2B5F1AQ37647174-99F7BD6C-C58E-43EC-9095-CC94E720DC9AQ38630770-9674557D-865C-40A2-95B4-EA0479FAA7F7Q38799847-D4FADFE3-BF61-48BB-8672-B5A9EC725628Q38827675-1B35CEB0-1849-4F11-908C-D38204B92CAFQ38939466-1154DA38-A1DD-40D7-8AC1-7D2B462E97EDQ38959067-099105B1-6D54-4BCE-9240-B0CF03D3C9E7
P2860
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@ast
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en-gb
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@nl
type
label
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@ast
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en-gb
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@nl
prefLabel
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@ast
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en-gb
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@nl
P2093
P2860
P50
P3181
P1476
Long-acting inhaled therapy (b ...... COPD: a network meta-analysis
@en
P2093
Christopher J Cates
Kayleigh M Kew
Sofia Dias
P2860
P304
P3181
P356
10.1002/14651858.CD010844.PUB2
P577
2014-03-26T00:00:00Z